Skye Bioscience Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2012
Selling, General & Admin	7.85	6.09	4.92	4.34	4.39	4.36	3.55	3.53	3.74	2.5	Upgrade
Research & Development	5.82	6.01	2.93	1.94	2.24	0.33	0.31	0.94	0.58	0.23	Upgrade
Other Operating Expenses	21.06	6.21	0	0	0	0	0	0	0	0	Upgrade
Operating Expenses	34.74	18.31	7.85	6.29	6.63	4.69	3.86	4.47	4.32	2.73	Upgrade
Operating Income	-34.74	-18.31	-7.85	-6.29	-6.63	-4.69	-3.86	-4.47	-4.32	-2.73	Upgrade
Interest Expense / Income	0.91	0.67	0.77	0.71	1	0.09	0	0	0	0	Upgrade
Other Expense / Income	2	0.5	-0.1	-0.44	-8.69	14.41	-0.77	-1.29	0.52	-	Upgrade
Pretax Income	-37.64	-19.47	-8.52	-6.56	1.05	-19.19	-3.09	-3.18	-4.84	-2.73	Upgrade
Income Tax	0	0.01	0	0	0	0	0	0	0	0	Upgrade
Net Income	-37.64	-19.48	-8.52	-6.56	1.05	-19.19	-3.09	-3.18	-4.84	-2.73	Upgrade
Preferred Dividends	0	0	0	0	0	0	1.04	0.33	0	0	Upgrade
Net Income Common	-37.64	-19.48	-8.52	-6.56	1.05	-19.19	-4.14	-3.5	-4.84	-2.73	Upgrade
Shares Outstanding (Basic)	7	2	2	1	1	0	0	0	0	0	Upgrade
Shares Outstanding (Diluted)	7	2	2	1	1	0	0	0	0	0	Upgrade
Shares Change	215.43%	36.56%	75.70%	36.48%	39.95%	334.15%	47.28%	11.86%	64.58%	32.45%	Upgrade
EPS (Basic)	-5.37	-8.77	-5.00	-7.50	2.50	-40.00	-27.50	-42.50	-72.50	-67.50	Upgrade
EPS (Diluted)	-5.37	-8.77	-5.00	-7.50	-12.50	-40.00	-27.50	-42.50	-72.50	-67.50	Upgrade
Free Cash Flow	-13.96	-12.77	-6.57	-6.06	-6.03	-3.95	-3.35	-3.56	-3.73	-1.78	Upgrade
Free Cash Flow Per Share	-1.99	-5.75	-4.04	-6.57	-11.15	-8.14	-30.02	-47.03	-55.05	-43.20	Upgrade
Effective Tax Rate	-	-	-	-	0.15%	-	-	-	-	-	Upgrade
EBITDA	-36.61	-18.69	-7.72	-5.85	2.06	-19.1	-3.08	-3.16	-4.83	-2.73	Upgrade
Depreciation & Amortization	0.12	0.11	0.03	0	0	0	0.01	0.01	0.01	0	Upgrade
EBIT	-36.73	-18.81	-7.75	-5.85	2.05	-19.1	-3.09	-3.18	-4.84	-2.73	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).